权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody

使用新型双特异性抗体靶向治疗多个胶质母细胞瘤吞噬检查点

基本信息

批准号：
10212046
负责人：
Wen Jiang
金额：
$ 44.46万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-15 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10212046
关键词：
Adult Affect Anti-CD47 Antibodies Antigen-Presenting Cells Antigens Antitumor Response Binding Bispecific Antibodies Blood - brain barrier anatomy Bone Marrow Brain Brain Neoplasms CD47 gene Cell surface Cells Clinical Clinical Research Clinical Trials Collection Colorectal Cancer Colorectal Neoplasms Combined Modality Therapy Critical Pathways Cross-Priming Cyclic GMP Cytosol Cytotoxic T-Lymphocytes DNA Sequence Alteration Data Detection Development Disease Eating Effectiveness Ensure Feedback Glioblastoma Glioma Goals Human Hybrids Immune Immune Evasion Immune response Immune system Immunotherapeutic agent In Vitro Individual Inflammatory Innate Immune Response Interferon Type I Interferons Investigation Kinetics Knock-out Lead Leukocytes Ligands Major Histocompatibility Complex Malignant Neoplasms Malignant neoplasm of brain Mammary Neoplasms Mediating Microglia Molecular Mus Natural Immunity Pathway interactions Patient-Focused Outcomes Patients Pattern Phagocytes Phagocytosis Phagosomes Play Pre-Clinical Model Prediction of Response to Therapy Process Production Radiation Receptor Signaling Regimen Research Resistance Role Signal Transduction Stimulator of Interferon Genes T cell response T-Lymphocyte Therapeutic Therapeutic Effect Therapeutic antibodies Time Toll-like receptors Tumor Escape Tumor Immunity adaptive immunity anti-tumor immune response antigen-specific T cells base beta-2 Microglobulin blood-brain tumor barrier cancer immunotherapy cell killing clinically relevant conventional therapy human model immune checkpoint immune checkpoint blockade improved in vivo innate immune checkpoint innate immune sensing knockout animal macrophage malignant breast neoplasm mouse model neoplastic cell novel novel therapeutic intervention overexpression patient derived xenograft model pre-clinical receptor reconstitution response spatiotemporal standard care success therapeutic target treatment response treatment strategy tumor tumor DNA tumor growth

项目摘要

PROJECT SUMMARY Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. The disease is universally fatal with current standard treatment being ineffective and debilitating. Cancer immunotherapy has demonstrated remarkable clinical success against multiple aggressive cancers and growing evidence suggests that boosting the body’s immune system can help eliminate highly aggressive and advanced tumors, including those resistant to conventional therapies. Its effectiveness against GBM, however, remains unclear, with multiple clinical trials exploring cancer immunotherapy regimens for GBM failed to demonstrate significant improvement in patient outcomes. Our group and others have recently discovered that GBM cells overexpress innate checkpoint CD47 to evade detection and clearance by professional antigen presenting cells (APCs). The expression level of CD47 was also found to correlate with survival in GBM patients. However, multiple studies showed that blockade of CD47 provided modest survival benefit in preclinical models of human cancers and additional phagocytosis checkpoints such as the β2 microglobulin (B2m) subunit of MHC-I molecule have been identified to promote tumor immune evasion. Disruption of B2m interaction with its phagocyte receptor leukocyte Ig-like receptor B1 (LILRB1) promotes phagocytosis of a diverse collection of tumor cells that were resistant to CD47 blockade. Yet, when anti-CD47 and anti-B2m antibodies were administered independently, we did not observe improved GBM phagocytosis. Therefore, based on these findings, we hypothesize that simultaneous blockade of phagocytosis checkpoints CD47 and B2m will activate innate immune responses against GBM, leading to a potent and durable adaptive antitumor immunity. To this end, we developed a novel bispecific antibody (CD47-B2m) that readily crosses the blood brain barrier (BBB). Aim 1 of the proposal will mechanistically examine whether CD47-B2m can promote antigen-specific antitumor T cell responses by APCs through induced GBM cell phagocytosis. In Aim 2, we will investigate if innate immune sensing pathways are critical in bridging innate and adaptive antitumor immunity in the setting of phagocytosis checkpoint blockade by CD47-B2m. Finally, in Aim 3, we will evaluate the use of CD47-B2m as a novel immunotherapeutic for GBM in clinically relevant murine models of GBM as a monotherapy or in combination with radiation. We will also investigate potential molecular mechanisms that predict treatment responses. If successful, our study will provide important preclinical data supporting further investigation of a completely novel immunotherapeutic agent against GBM. Additionally, the results generated here will highlight the importance of bridging innate and adaptive immunity to produce the most optimal antitumor immune responses. The concept of targeting multiple phagocytosis checkpoints can be applied to potentially all human cancers, and if successful may provide a new strategy to enhance the effectiveness of cancer immunotherapies.

项目总结